Year-end Sale % OFF 
Abstract
Background: The long-acting basal insulin analogue insulin glargine is used to improve glycaemic control in people with type 2 diabetes (PWD2). Insulin glargine 100 U/mL (Gla-100) was shown to improve glycaemic control for PWD2 compared with standard-of-care in the 7-year follow-up from the ORIGIN trial (NCT00069784). More recently, a longer-acting insulin glargine 300 units/mL (Gla-300) was compared with Gla-100 in PWD2 in the non-inferiority EDITION-3 trial (NCT01676220); after 12 months, Gla-300 demonstrated similar glycaemic control compared with Gla-100.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
